Symbols / SHPH Stock $1.03 +9.77% Shuttle Pharmaceuticals Holdings, Inc.
SHPH (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Ratings
Current target
$1.03
Low
—
High
—
Mean
—
- Shuttle Pharmaceuticals announces $3.5 million public offering - MSN Sun, 26 Apr 2026 21
- Shuttle Pharma (SHPH) proxy asks investors to OK major reverse split range - Stock Titan Mon, 20 Apr 2026 21
- Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00 - Yahoo Finance Mon, 03 Nov 2025 08
- Why Does SHPH Stock Dip? - StocksToTrade Fri, 21 Nov 2025 08
- Shuttle Pharmaceuticals stock falls after closing Molecule.ai acquisition - Investing.com Fri, 21 Nov 2025 08
- AI drug discovery firm Shuttle Pharma raises $3.5M in public offering - Stock Titan Fri, 06 Mar 2026 08
- Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill ue, 20 Jan 2026 08
- SHPH Stock Analysis: Shuttle Pharmaceuticals Holdings Inc. trades at 0.69 with 1.66 percent gain - Cổng thông tin điện tử Tỉnh Sơn La Wed, 01 Apr 2026 07
- Shuttle Pharmaceuticals CFO Resigns, Interim CEO Steps In - The Globe and Mail Sat, 29 Nov 2025 08
- Shuttle Pharmaceuticals’ Stock Surges Amid Strategic Developments - StocksToTrade ue, 20 Jan 2026 08
- Shuttle Pharma secures $2.5 million in above-market financing deal - Investing.com Mon, 03 Nov 2025 08
- Shuttle Pharma's new AI agent is built for multi-step drug research - Stock Titan hu, 26 Mar 2026 07
- Shuttle Pharmaceuticals says reverse stock split to become effective June 16 - Yahoo Finance Fri, 13 Jun 2025 07
- Wondering what's happening in today's pre-market session? - ChartMill ue, 20 Jan 2026 08
- Utah lets AI refill meds—and how a drug discovery platform fits this shift - Stock Titan ue, 13 Jan 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
11.92
+54.84%
|
7.70
+30.61%
|
5.89
+151.40%
|
2.34
|
| Research And Development |
|
4.05
+12.05%
|
3.62
+2.89%
|
3.52
+235.80%
|
1.05
|
| Selling General And Administration |
|
7.86
+92.82%
|
4.08
+71.66%
|
2.38
+83.22%
|
1.30
|
| General And Administrative Expense |
|
7.86
+92.82%
|
4.08
+71.66%
|
2.38
+83.22%
|
1.30
|
| Other Gand A |
|
7.86
+92.82%
|
4.08
+71.66%
|
2.38
+83.22%
|
1.30
|
| Total Expenses |
|
11.92
+54.84%
|
7.70
+30.61%
|
5.89
+151.40%
|
2.34
|
| Operating Income |
|
-11.92
-54.84%
|
-7.70
-30.61%
|
-5.89
-151.40%
|
-2.34
|
| Total Operating Income As Reported |
|
-11.92
-54.84%
|
-7.70
-30.61%
|
-5.89
-151.40%
|
-2.34
|
| EBITDA |
|
-11.36
-46.04%
|
-7.78
-94.94%
|
-3.99
+11.50%
|
-4.51
|
| Normalized EBITDA |
|
-11.63
-54.43%
|
-7.53
-29.68%
|
-5.81
-129.71%
|
-2.53
|
| Reconciled Depreciation |
|
0.29
+5210.40%
|
0.01
-19.79%
|
0.01
+14.05%
|
0.01
|
| EBIT |
|
-11.65
-49.66%
|
-7.78
-94.74%
|
-4.00
+11.47%
|
-4.52
|
| Total Unusual Items |
|
0.27
+207.66%
|
-0.25
-113.72%
|
1.82
+191.63%
|
-1.98
|
| Total Unusual Items Excluding Goodwill |
|
0.27
+207.66%
|
-0.25
-113.72%
|
1.82
+191.63%
|
-1.98
|
| Special Income Charges |
|
0.34
+141.11%
|
-0.83
-74.66%
|
-0.48
+65.77%
|
-1.39
|
| Other Special Charges |
|
-0.34
-141.11%
|
0.83
+74.66%
|
0.48
-65.77%
|
1.39
|
| Write Off |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-11.72
-28.18%
|
-9.14
-38.71%
|
-6.59
-31.96%
|
-5.00
|
| Pretax Income |
|
-11.72
-28.18%
|
-9.14
-38.71%
|
-6.59
-31.96%
|
-5.00
|
| Net Non Operating Interest Income Expense |
|
-0.07
+94.72%
|
-1.32
+47.46%
|
-2.52
-275.20%
|
-0.67
|
| Interest Expense Non Operating |
|
0.07
-94.79%
|
1.36
-47.59%
|
2.60
+439.89%
|
0.48
|
| Net Interest Income |
|
-0.07
+94.72%
|
-1.32
+47.46%
|
-2.52
-275.20%
|
-0.67
|
| Interest Expense |
|
0.07
-94.79%
|
1.36
-47.59%
|
2.60
+439.89%
|
0.48
|
| Interest Income Non Operating |
|
0.00
-97.14%
|
0.04
-51.80%
|
0.08
|
0.00
|
| Interest Income |
|
0.00
-97.14%
|
0.04
-51.80%
|
0.08
|
0.00
|
| Other Income Expense |
|
0.26
+309.22%
|
-0.13
-106.97%
|
1.82
+191.63%
|
-1.98
|
| Other Non Operating Income Expenses |
|
-0.00
-102.73%
|
0.12
|
—
|
0.33
|
| Gain On Sale Of Security |
|
-0.07
-112.73%
|
0.58
-74.52%
|
2.29
+490.19%
|
-0.59
|
| Tax Provision |
|
—
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-11.72
-28.18%
|
-9.14
-38.71%
|
-6.59
-31.96%
|
-5.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
-11.72
-28.18%
|
-9.14
-38.71%
|
-6.59
-31.96%
|
-5.00
|
| Net Income From Continuing And Discontinued Operation |
|
-11.72
-28.18%
|
-9.14
-38.71%
|
-6.59
-31.96%
|
-5.00
|
| Net Income Continuous Operations |
|
-11.72
-28.18%
|
-9.14
-38.71%
|
-6.59
-31.96%
|
-5.00
|
| Normalized Income |
|
-11.99
-34.78%
|
-8.90
-5.79%
|
-8.41
-178.94%
|
-3.01
|
| Net Income Common Stockholders |
|
-11.72
-28.18%
|
-9.14
-38.71%
|
-6.59
+2.29%
|
-6.75
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
0.00
-100.00%
|
0.94
|
| Diluted EPS |
|
—
|
-82.60
+6.40%
|
-88.25
+29.96%
|
-126.00
|
| Basic EPS |
|
—
|
-79.65
+9.75%
|
-88.25
+29.96%
|
-126.00
|
| Basic Average Shares |
|
—
|
0.11
+53.79%
|
0.07
+39.51%
|
0.05
|
| Diluted Average Shares |
|
—
|
0.12
+54.71%
|
0.07
+39.51%
|
0.05
|
| Diluted NI Availto Com Stockholders |
|
-11.72
-28.18%
|
-9.14
-38.71%
|
-6.59
+2.29%
|
-6.75
|
| Preferred Stock Dividends |
|
—
|
—
|
—
|
0.81
|
| Total Other Finance Cost |
|
—
|
—
|
0.10
-45.11%
|
0.19
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
10.48
+317.99%
|
2.51
-57.89%
|
5.95
-31.22%
|
8.65
|
| Current Assets |
|
0.50
-77.25%
|
2.21
-60.47%
|
5.59
-34.80%
|
8.58
|
| Cash Cash Equivalents And Short Term Investments |
|
0.33
-82.61%
|
1.92
-64.86%
|
5.46
-35.09%
|
8.42
|
| Cash And Cash Equivalents |
|
0.33
-82.61%
|
1.92
-25.47%
|
2.58
-69.39%
|
8.42
|
| Cash Equivalents |
|
0.08
+6221.70%
|
0.00
-99.88%
|
1.03
-65.86%
|
3.01
|
| Cash Financial |
|
0.26
-86.56%
|
1.92
+23.79%
|
1.55
-71.35%
|
5.41
|
| Other Short Term Investments |
|
—
|
0.00
-100.00%
|
2.89
|
0.00
|
| Receivables |
|
—
|
0.00
-100.00%
|
0.01
|
0.00
|
| Accounts Receivable |
|
—
|
—
|
—
|
—
|
| Accrued Interest Receivable |
|
—
|
0.00
-100.00%
|
0.01
|
0.00
|
| Prepaid Assets |
|
0.17
-41.91%
|
0.29
+154.01%
|
0.11
-28.96%
|
0.16
|
| Other Current Assets |
|
0.00
|
—
|
—
|
—
|
| Total Non Current Assets |
|
9.97
+3276.43%
|
0.30
-17.66%
|
0.36
+377.07%
|
0.08
|
| Net PPE |
|
0.12
-59.47%
|
0.30
-17.66%
|
0.36
+422.06%
|
0.07
|
| Gross PPE |
|
0.12
-59.47%
|
0.30
-17.66%
|
0.36
+95.40%
|
0.18
|
| Accumulated Depreciation |
|
—
|
—
|
-0.12
-5.93%
|
-0.11
|
| Machinery Furniture Equipment |
|
—
|
—
|
—
|
0.01
|
| Other Properties |
|
0.12
-59.47%
|
0.30
-17.66%
|
0.36
+95.40%
|
0.18
|
| Goodwill And Other Intangible Assets |
|
9.84
|
0.00
|
—
|
—
|
| Non Current Deferred Assets |
|
0.01
|
0.00
|
—
|
—
|
| Other Non Current Assets |
|
—
|
—
|
—
|
0.01
|
| Total Liabilities Net Minority Interest |
|
8.22
+357.48%
|
1.80
-5.21%
|
1.90
+94.32%
|
0.98
|
| Current Liabilities |
|
7.97
+419.43%
|
1.53
+47.16%
|
1.04
+6.82%
|
0.98
|
| Payables And Accrued Expenses |
|
5.89
+884.27%
|
0.60
+51.97%
|
0.39
+73.17%
|
0.23
|
| Payables |
|
5.89
+887.21%
|
0.60
+110.59%
|
0.28
+119.20%
|
0.13
|
| Accounts Payable |
|
1.45
+143.68%
|
0.60
+110.59%
|
0.28
+119.20%
|
0.13
|
| Other Payable |
|
4.44
|
—
|
—
|
—
|
| Dividends Payable |
|
—
|
—
|
—
|
0.00
|
| Current Accrued Expenses |
|
0.00
-100.00%
|
0.00
-98.38%
|
0.11
+12.55%
|
0.10
|
| Current Debt And Capital Lease Obligation |
|
0.08
-91.75%
|
0.94
+44.24%
|
0.65
-13.34%
|
0.75
|
| Current Debt |
|
—
|
0.87
+46.72%
|
0.60
-13.05%
|
0.69
|
| Other Current Borrowings |
|
—
|
0.68
+14.80%
|
0.60
|
—
|
| Current Capital Lease Obligation |
|
0.08
+26.74%
|
0.06
+16.06%
|
0.05
-16.47%
|
0.06
|
| Other Current Liabilities |
|
2.00
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.25
-3.31%
|
0.26
-69.15%
|
0.85
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.15
-34.92%
|
0.24
-45.79%
|
0.44
|
0.00
|
| Long Term Debt |
|
—
|
—
|
0.14
|
—
|
| Long Term Capital Lease Obligation |
|
0.15
-34.92%
|
0.24
-21.71%
|
0.30
|
0.00
|
| Stockholders Equity |
|
2.25
+217.91%
|
0.71
-82.51%
|
4.06
-47.18%
|
7.68
|
| Common Stock Equity |
|
2.25
+217.91%
|
0.71
-82.51%
|
4.06
-47.18%
|
7.68
|
| Capital Stock |
|
0.00
+900.00%
|
0.00
-90.00%
|
0.00
+17.65%
|
0.00
|
| Common Stock |
|
0.00
+900.00%
|
0.00
-90.00%
|
0.00
+17.65%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
1.92
+1079.78%
|
0.16
+102.95%
|
0.08
+18.13%
|
0.07
|
| Ordinary Shares Number |
|
1.92
+1079.78%
|
0.16
+102.95%
|
0.08
+18.13%
|
0.07
|
| Additional Paid In Capital |
|
48.55
+37.60%
|
35.29
+19.66%
|
29.49
+11.20%
|
26.52
|
| Retained Earnings |
|
-46.30
-33.90%
|
-34.58
-35.96%
|
-25.43
-34.99%
|
-18.84
|
| Total Equity Gross Minority Interest |
|
2.25
+217.91%
|
0.71
-82.51%
|
4.06
-47.18%
|
7.68
|
| Total Capitalization |
|
2.25
+217.91%
|
0.71
-83.08%
|
4.19
-45.42%
|
7.68
|
| Working Capital |
|
-7.46
-1202.27%
|
0.68
-85.12%
|
4.55
-40.14%
|
7.60
|
| Invested Capital |
|
2.25
+42.36%
|
1.58
-66.92%
|
4.79
-42.76%
|
8.36
|
| Total Debt |
|
0.23
-80.22%
|
1.17
+7.89%
|
1.09
+45.36%
|
0.75
|
| Net Debt |
|
—
|
—
|
—
|
—
|
| Capital Lease Obligations |
|
0.23
-22.36%
|
0.30
-16.15%
|
0.36
+467.64%
|
0.06
|
| Net Tangible Assets |
|
-7.59
-1169.84%
|
0.71
-82.51%
|
4.06
-47.18%
|
7.68
|
| Tangible Book Value |
|
-7.59
-1169.84%
|
0.71
-82.51%
|
4.06
-47.18%
|
7.68
|
| Current Notes Payable |
|
0.00
-100.00%
|
0.19
|
0.00
-100.00%
|
0.69
|
| Derivative Product Liabilities |
|
0.10
+294.32%
|
0.03
-93.90%
|
0.41
|
0.00
|
| Interest Payable |
|
0.00
-100.00%
|
0.00
-98.38%
|
0.11
+12.55%
|
0.10
|
| Other Equity Interest |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-9.48
-29.40%
|
-7.33
-31.29%
|
-5.58
-109.31%
|
-2.67
|
| Cash Flow From Continuing Operating Activities |
|
-9.48
-29.40%
|
-7.33
-31.29%
|
-5.58
-109.31%
|
-2.67
|
| Net Income From Continuing Operations |
|
-11.72
-28.18%
|
-9.14
-38.71%
|
-6.59
-31.96%
|
-5.00
|
| Depreciation Amortization Depletion |
|
0.29
+5210.40%
|
0.01
-19.79%
|
0.01
+14.05%
|
0.01
|
| Depreciation |
|
0.29
+5210.40%
|
0.01
-19.79%
|
0.01
+14.05%
|
0.01
|
| Depreciation And Amortization |
|
0.29
+5210.40%
|
0.01
-19.79%
|
0.01
+14.05%
|
0.01
|
| Other Non Cash Items |
|
0.06
-95.18%
|
1.29
-46.78%
|
2.42
+10046.43%
|
-0.02
|
| Stock Based Compensation |
|
0.93
+259.19%
|
0.26
+42.75%
|
0.18
-23.40%
|
0.24
|
| Asset Impairment Charge |
|
0.11
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
0.42
+67.38%
|
0.25
+114.28%
|
-1.74
-167.78%
|
2.57
|
| Gain Loss On Investment Securities |
|
0.07
+112.73%
|
-0.58
+73.70%
|
-2.22
-385.69%
|
0.78
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
+102.73%
|
-0.12
-71.24%
|
-0.07
|
0.00
|
| Change In Working Capital |
|
0.54
+289.18%
|
0.14
-37.04%
|
0.22
+147.67%
|
-0.46
|
| Change In Receivables |
|
0.00
-100.00%
|
0.01
+200.00%
|
-0.01
|
0.00
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
0.00
|
| Change In Prepaid Assets |
|
0.12
+169.12%
|
-0.18
-477.72%
|
0.05
+129.87%
|
-0.16
|
| Change In Payables And Accrued Expense |
|
0.42
+40.39%
|
0.30
+80.33%
|
0.17
+155.31%
|
-0.30
|
| Change In Accrued Expense |
|
-0.00
+86.55%
|
-0.01
-207.74%
|
0.01
-82.29%
|
0.07
|
| Change In Payable |
|
0.42
+35.01%
|
0.31
+103.36%
|
0.15
+141.60%
|
-0.37
|
| Change In Account Payable |
|
0.42
+35.01%
|
0.31
+103.36%
|
0.15
+141.60%
|
-0.37
|
| Change In Other Working Capital |
|
-0.00
-959.79%
|
0.00
-98.21%
|
0.02
+381.06%
|
-0.01
|
| Change In Other Current Assets |
|
0.00
|
0.00
-100.00%
|
0.01
|
0.00
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
-0.07
|
| Investing Cash Flow |
|
-3.06
-204.83%
|
2.92
+203.04%
|
-2.83
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-3.06
-204.83%
|
2.92
+203.04%
|
-2.83
|
0.00
|
| Net PPE Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.02
|
0.00
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.02
|
0.00
|
| Capital Expenditure |
|
-3.06
|
—
|
-0.02
|
—
|
| Capital Expenditure Reported |
|
-0.01
|
0.00
|
—
|
—
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
2.92
+203.74%
|
-2.81
|
0.00
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-0.04
+98.55%
|
-3.00
|
0.00
|
| Sale Of Investment |
|
0.00
-100.00%
|
2.96
+1475.00%
|
0.19
|
0.00
|
| Net Intangibles Purchase And Sale |
|
-3.04
|
0.00
|
—
|
—
|
| Purchase Of Intangibles |
|
-3.04
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
10.95
+191.66%
|
3.76
+46.11%
|
2.57
-75.71%
|
10.58
|
| Cash Flow From Continuing Financing Activities |
|
10.95
+191.66%
|
3.76
+46.11%
|
2.57
-75.71%
|
10.58
|
| Net Issuance Payments Of Debt |
|
-0.19
-242.56%
|
0.13
-95.89%
|
3.25
+440.94%
|
0.60
|
| Issuance Of Debt |
|
0.00
-100.00%
|
1.04
-73.57%
|
3.94
+504.72%
|
0.65
|
| Repayment Of Debt |
|
-0.19
+79.01%
|
-0.91
-32.25%
|
-0.69
-1270.95%
|
-0.05
|
| Long Term Debt Issuance |
|
—
|
0.79
-79.92%
|
3.94
+555.05%
|
0.60
|
| Long Term Debt Payments |
|
—
|
-0.85
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
-0.06
-101.44%
|
3.94
+555.05%
|
0.60
|
| Short Term Debt Issuance |
|
0.00
-100.00%
|
1.04
|
0.00
-100.00%
|
0.05
|
| Short Term Debt Payments |
|
-0.19
+79.01%
|
-0.91
-32.25%
|
-0.69
-1270.95%
|
-0.05
|
| Net Short Term Debt Issuance |
|
-0.19
-242.56%
|
0.13
+119.47%
|
-0.69
|
0.00
|
| Net Common Stock Issuance |
|
9.49
+137.68%
|
3.99
|
0.00
-100.00%
|
10.00
|
| Cash Dividends Paid |
|
0.00
|
0.00
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
2.28
+313293.14%
|
0.00
+100.21%
|
-0.34
|
—
|
| Net Other Financing Charges |
|
-0.56
-111.09%
|
-0.26
+21.01%
|
-0.33
-1826.19%
|
-0.02
|
| Changes In Cash |
|
-1.59
-141.69%
|
-0.66
+88.76%
|
-5.84
-173.82%
|
7.91
|
| Beginning Cash Position |
|
1.92
-25.47%
|
2.58
-69.39%
|
8.42
+1567.60%
|
0.50
|
| End Cash Position |
|
0.33
-82.61%
|
1.92
-25.47%
|
2.58
-69.39%
|
8.42
|
| Free Cash Flow |
|
-12.54
-71.12%
|
-7.33
-30.84%
|
-5.60
-110.03%
|
-2.67
|
| Interest Paid Supplemental Data |
|
0.13
+44.70%
|
0.09
-47.46%
|
0.16
+320.42%
|
0.04
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Change In Interest Payable |
|
-0.00
+86.55%
|
-0.01
-207.74%
|
0.01
-82.29%
|
0.07
|
| Common Stock Issuance |
|
9.49
+137.68%
|
3.99
|
0.00
-100.00%
|
10.00
|
| Interest Paid CFF |
|
-0.07
+31.02%
|
-0.11
|
—
|
—
|
| Interest Paid CFO |
|
-0.12
|
0.00
|
—
|
—
|
| Issuance Of Capital Stock |
|
9.49
+137.68%
|
3.99
|
0.00
-100.00%
|
10.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-31 View
- 8-K2026-03-10 View
- 8-K2026-02-17 View
- 8-K2026-02-02 View
- 8-K2026-01-12 View
- 8-K2025-12-29 View
- 8-K2025-11-28 View
- 8-K2025-11-26 View
- 8-K2025-11-21 View
- 8-K2025-11-17 View
- 10-Q2025-11-13 View
- 8-K2025-11-07 View
- 8-K2025-10-21 View
- 8-K2025-09-22 View
- 8-K2025-09-18 View
- 8-K2025-09-17 View
- 8-K2025-09-08 View
- 8-K2025-09-05 View
- 42025-08-13 View
- 10-Q2025-08-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|